Access Biotechnology — 2018 Investments

1 investments dated 2018 · listed companies and verified rows first · show all

Pandion Therapeuticspandiontx.comJan 2018acquired by Merck · Feb 2021 · $1.9B

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Co-investorsJDRF T1D Fund Mission Biocapital RA Capital SR One Capital Management Polaris Partners Versant Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.